Expertise in
2
conditions

Dr. James Strauss

Hematology
Dr. Cynthia Swayze Smith D.O
7777 Forest Ln Bldg C, 
Dallas, TX 
Offers Telehealth
Expertise in
2
conditions
Dr. Cynthia Swayze Smith D.O
7777 Forest Ln Bldg C, 
Dallas, TX 

Overview

James Strauss is a Hematologist in Dallas, Texas. Dr. Strauss is highly rated in 2 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Adult Soft Tissue Sarcoma, Pancreatic Cancer, and Lung Cancer.

His clinical research consists of co-authoring 15 peer reviewed articles and participating in 36 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Dr. Cynthia Swayze Smith D.O
7777 Forest Ln Bldg C, Dallas, TX 75230

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

36 Clinical Trials

An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: April 08, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Enrollment Status: Active_not_recruiting
Publish Date: March 31, 2026
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
Enrollment Status: Terminated
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drugs: MBG453, Hypomethylating agents
Study Phase: Phase 2
A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 27, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor, EGFR, or ALK Inhibitor.
A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor, EGFR, or ALK Inhibitor.
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Biological
Study Drugs: CAB-AXL-ADC, PD-1 Inhibitor
Study Phase: Phase 2
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Biological
Study Drugs: Enoblituzumab, Pembrolizumab, MGA012 Anti-PD-1 Antibody
Study Phase: Phase 1
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: May 08, 2025
Intervention Type: Drug
Study Drug: Surufatinib+Tislelizumab
Study Phase: Phase 1/Phase 2
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Enrollment Status: Completed
Publish Date: March 26, 2025
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

15 Total Publications

First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.
First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.
Journal: Journal of hematology & oncology
Published: July 19, 2025
Similar Doctors
Expertise in
39
conditions
Dr. Farrukh Awan
Hematology | Oncology
Expertise in
39
conditions
Dr. Farrukh Awan
Hematology | Oncology

UT Southwestern-Bill And Rita Clements Advanced Medical Imaging Center

2201 Inwood Rd, 
Dallas, TX 
 (6.4 miles away)
214-645-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Farrukh Awan is a Hematologist and an Oncologist in Dallas, Texas. Dr. Awan is highly rated in 39 conditions, according to our data. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
8
conditions
Dr. Jaime Brugarolas
Hematology
Expertise in
8
conditions
Dr. Jaime Brugarolas
Hematology

University Of Texas Southwestern Medical Center

5323 Harry Hines Blvd, 
Dallas, TX 
 (6.7 miles away)
214-645-0624
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jaime Brugarolas is a Hematologist in Dallas, Texas. Dr. Brugarolas is highly rated in 8 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Familial Wilms Tumor 2, Nephrectomy, and Thrombectomy.

Expertise in
22
conditions
Dr. Yazan Madanat
Hematology
Expertise in
22
conditions
Dr. Yazan Madanat
Hematology

Office

2201 Inwood Rd, 
Dallas, TX 
 (6.4 miles away)
214-645-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Yazan Madanat is a Hematologist in Dallas, Texas. Dr. Madanat is highly rated in 22 conditions, according to our data. His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. James Strauss

How do I make an appointment with Dr. James Strauss?

You can book an appointment with Dr. James Strauss by calling their office at 972-566-3000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. James Strauss a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. James Strauss is classified as an Advanced expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. James Strauss specialize in?

While Dr. James Strauss is a Hematology, they have specific expertise in Ovarian Cancer, Adult Soft Tissue Sarcoma, and Pancreatic Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. James Strauss participate in research or clinical trials?

Yes. Dr. James Strauss has published 15 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. James Strauss's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. James Strauss accept my insurance?

Dr. James Strauss accepts most major insurance plans, including Cigna and Friday Health. We recommend calling the office directly at 972-566-3000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Strauss's expertise for a condition
ConditionClose
      View All 22 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile